Dublin, June 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Autoinjectors Market, 2016 - 2026" report to their offering.
The Global Autoinjectors Market, 2016-2026' report provides a comprehensive analysis of the current state of autoinjectors market and the likely future evolution of these devices over the next decade. Starting with an overview of self-administration devices, the report elaborates on the origin / history of autoinjectors, their components and advantages offered by different categories of autoinjectors.
It also covers information on needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes that are incorporated as primary drug containers in autoinjectors.
One of the key objectives of the study is to enumerate various autoinjectors available in the market, combination products currently available / being developed and the corresponding market potential across different therapeutic areas.
Amongst other elements, the report elaborates on the following key areas:
- The current state of the market with respect to key players, routes of administration, primary drug containers, usability, indications and drugs being targeted.
- 2 X 2 matrices depicting the product competitiveness and supplier power across the growing landscape of disposable and reusable autoinjectors.
- Detailed case studies on the drugs that have been potential targets for autoinjectors.
- List of likely candidates for delivery via autoinjectors based upon their route of administration, targeted indication and dosage regime.
- Detailed company profiles of the key autoinjector manufacturers as well as emerging players that are trying to build a foothold in this industry.
- The future growth opportunities likely to drive the market in the short term and long term.
The study also focuses on analyzing the existing market size and potential future growth of these drug delivery devices across different therapeutic classes, routes of administration and extent of usability. The report provides sales forecast for the overall autoinjectors market for the period 2016 - 2026. It takes into account the price variation that is likely to occur as a result of mass adoption and increased competition.
For the purposes of the study, we interviewed important stakeholders to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. 2015 is the base year; actual figures have been sourced and analyzed from publicly available information. Unless otherwise specified, all figures are presented in USD.
Example Highlights
- During our research, we identified over 80 autoinjectors being developed or commercially available by more than 20 companies. Over 50 drugs as combination products have been commercialized so far; several companies such as Amgen, GSK, Sanofi and Palatin Technologies are testing their late stage pipeline drugs with autoinjectors.
- Most of the autoinjectors being developed are disposable devices, contributing a share of 62%; reusable / rechargeable / electronic autoinjectors have also emerged providing options for multiple dosing of the drugs.
- Some of the established pharmaceutical stakeholders working in this domain include BD, Bespak, Changzhou Delfu, Elcam Medical, DALI Medical Devices, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico, West Pharmaceutical Services and Ypsomed. Several new / small companies have entered with their innovative technologies and devices. Examples of such innovators include Amedra Pharmaceuticals, ChemProtect SK, Future Injection Technologies, Haselmeier AG, Kaleo Pharma, Nuance, Nemera, Oval Medical Technologies, Unilife and Xeris Pharmaceuticals.
- Developers are focusing on introducing a variety of advanced features to make these devices more user-friendly. Specific examples include push-on-skin release, one-handed operation, twist & mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek designs. Smart electronic autoinjectors are being developed featuring bluetooth connectivity, LCD screen and special software to connect the device or part of the device with computer systems to maintain injection records. Some of the devices, such as Safelia autoinjector (Nemera) and Syrina AR (Bespak), are also capable of delivering drugs with high volume and high viscosity.
- A variety of novel technologies have emerged for the development of autoinjectors. Examples of such technologies include Breeze technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft technology (Bespak), Rotaject Pressure Release technology, NIT technology, Negasai spring technology and Pushclick technology (SHL Group).
- Although autoinjectors have been in the market for over two decades, the market is still evolving. There is widespread optimism that such devices hold significant opportunity for the pharmaceutical companies; the rapidly evolving pipeline of biologics and biosimilars will act as a major driver.
- We anticipate the global autoinjectors market to grow at an annualized growth rate of over 8% in the next ten years. Launch in emerging regions such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Primary Drug Containers in Autoinjectors
5. Autoinjectors: Current Market Landscape
6. Case Studies
7. Key Players
8. Emerging Players
9. Global Autoinjectors Market Forecast, 2016 - 2026
10. Future Growth Opportunities
11. Interview Transcripts
12. Conclusion
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organizations
- 3P Limited
- ALK-Abelló A/S
- AbbVie
- Ablynx
- Aguettant
- Allergy Therapeutics
- Alliance Healthcare
- Allozyne (Acquired by MedImmune)
- Amag Pharmaceuticals
- Amedra Pharmaceuticals (Acquired by Impax Laboratories)
- Amgen
- Antares Phama
- Aptar Pharma
- Arte Corporation
- Aventis Pharma
- Bang & Olufsen Medicom
- Bayer Healthcare
- Becton Dickinson & Co.
- Bespak
- Biogen Idec
- Bioprojet
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Brunswick Biomedical Corporation
- Cambridge Capital Group
- Cambridge Consultants
- Celgene Corporation
- Central Texas Angel Network
- Changzhou Delfu Technology
- ChemProtect SK
- Chugai Pharmaceutical Co. Ltd
- CiToxLab
- Consort Medical
- Cytheris
- CytoDyn
- DALI Medical Devices
- Daikyo Seiko
- Disetronic
- Dr. Reddy's Laboratories
- EMD Serono
- Elcam Medical
- Eli Lilly
- Emergent Biosolutions
- Exsulin
- FFT Medical
- Future Injection Technologies
- Gerresheimer
- GlaxoSmithKline
- Global Pharma
- Globe Medical Tech
- Haselmeier AG
- Hemispherx Bioscience
- Hoffmann-La Roche
- Hospira
- Immune Response Biopharma
- Immunex
- Injectech
- Ionis Pharmaceuticals
- JHP Pharmaceuticals
- Janssen Biotech
- Jiangsu Delfu medical device
- Johnson & Johnson
- Kaleo (formerly known as Intelliject)
- King Pharmaceuticals
- Kisling AG
- Labrys Biologics (Acquired by Teva)
- Lincoln Medical (Acquired by Bioprojet Pharma)
- Lineage Therapeutics
- LyoGo
- MSD Animal Health
- MedPro
- Medac Pharma
- Medeca Pharma
- Medical Valley Alliance
- Merck
- Merck Serono
- Meridian Medical Technologies
- Merz Pharmaceuticals
- Mylan
- National Health Service
- Nemera
- Nipro Corporation (Acquired MGlas)
- Novartis
- Novo Nordisk
- Nuance Design
- Nuova Ompi
- Nuron Biotech
- Otsuka Pharmaceuticals
- Oval Medical Technologies
- Owen Mumford
- PA Consulting Group
- PDL BioPharma
- PHC Injection Device Technologies
- Palatin Technologies
- Pfizer
- Pharma-Pen
- PhaseBio Pharmaceuticals
- Plas-Tech Engineering
- Project Pharmaceutics
- Redmile Group
- Regeneron Pharmaceuticals
- Revolutions Medical
- Roselabs Bioscience
- SCHOTT AG
- SKINSORB
- Sabby Management
- Sanofi
- Sanofi Pasteur
- Santarus
- Scandinavian Health Limited Group
- School of Medicine at the University of Texas Health Science Center San Antonio
- Schreiner MediPharm
- Sciele Pharma (Now Known as Shionogi Pharma)
- Shandong Weigao Group
- SiO2 Medical Products
- SiliCycle
- Sumitomo Dainippon Pharma
- Sun Pharma
- Survival Technologies
- Taisei Kako
- Takeda
- Team Consulting
- Terumo Corporation
- Teva Pharma Industries
- Texas Diabetes Institute (TDI) of the University Health System
- The Cambridge Angels
- The McNair Group
- The Medical House (TMH)
- Tonghua Dongbao Pharmaceutical
- UCB
- US Medical Instruments
- US WorldMeds
- Uman Pharma
- Unilife Corporation
- Union Medico
- Valeant Pharmaceutical International
- Vetter Pharma
- West Pharmaceutical Services
- Windgap Medical
- Xeris Pharmaceuticals
- Ypsomed Delivery Systems
- Zion Clinical Pharmacy
- medac GmbH
For more information visit http://www.researchandmarkets.com/research/7zsh6w/global